The clinical diagnosis, treatment and prognosis of lymphoma-associated hemophagocytic syndrome: A report of three cases and literature review

周玉兰,李菲,张荣艳,李蒲,纪德香,胥倩,魏艳琳,黄瑞滨,伍世礼
DOI: https://doi.org/10.3781/j.issn.1000-7431.2014.05.013
2014-01-01
Tumori
Abstract:Objective: To improve understanding of clinical diagnosis, treatment and prognosis of lymphoma-associated hemophagocytic syndrome (LAHS) through retrospective review of medical records of three patients with LAHS and literature review. Methods: Three patients with LAHS hosptalized in Department of Hematology, First Affiliated Hospital of Nanchang University between April and August 2013 were collected and their medical records were retrospectively analyzed. A review of related literatures was also performed. Results: All three cases met the diagnostic criteria of hemophagocytic syndrome (HPS). Of the three patients, two patients had a primary disease of peripheral T-cell lymphoma and one had a primary disease of aggressive natural killer cell leukemia. Haemophagocytic phenomenon was evidenced by bone marrow aspiration or bone marrow biopsy in these three patients. One patient was infected with Epstein-Barr virus (EBV). One patient treated by high-dose methylprednisolone in combination with E-CHOP regimen has survived for 65 days so far, whereas the other two patients only survived for 27 and 31 days, respectively. Conclusion: LAHS is a disease with a rapid-onset and a high mortality, and can be easily confused with agnogenic or EBV-associated HPS. The evidence of lymphoma should be obtained through repeated biopsies. Controling the cytokine strom and chemotherapy for lymphoma may be more suitable for patients with LAHS. DOI:10.3781/j.issn.1000-7431.2014.05.013
What problem does this paper attempt to address?